Stocks · Health care · Pharmaceutical Preparations

GALECTIN THERAPEUTICS INC

GALT Clue Score21
United States Fiscal year ends December CIK 0001133416 Results filed 14 Aug 2026

What the insiders did Net selling

By person

10 insiders · 59 transactions
6.8×

Joel Lewis holds 6.8 times base salary in stock. $4.27M of shares against $624.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Joel Lewis last reported holding, valued at $5.13, the price Common Stock was last bought or sold at on the open market here, on 14 Jul 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Harold H. Shlevin
Director
—
$1.56M (14) scheduled
−$1.56M
26,123
$133.89K
−7.1%
Khurram Jamil
Chief Medical Officer
—
$1.44M (17) scheduled
−$1.44M
0
$0.00
—
10X Fund, L.P. entity
10% owner
—
$1.27M (4)
−$1.27M
5,614,457
$28.78M
−5.0%
Jack W Callicutt
Chief Financial Officer
—
$744.12K (11) scheduled
−$744.12K
7,614
$39.02K
0.0%
Joel Lewis
President and CEO
—
$523.99K (7) scheduled
−$523.99K
832,592
$4.27M
−6.3%
Kevin D Freeman
Director
$19.51K (1)
—
+$19.51K
55,269
$283.26K
+59.0%
Kary Eldred
Director
$6.03K (3)
—
+$6.03K
65,682
$336.63K
+32.7%
Richard E Uihlein
Director
—
—
—
55,046,519
$282.12M
+166.9%
James C Czirr
10% owner
—
—
—
1,045,541
$5.36M
+41.0%
Richard A. Zordani Jr.
Director
—
—
—
42,083
$215.68K
+31.2%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.